EQ Stock: Equillium, Inc. Stock Price, Analysis & Insights
Get live eq stock price $1.61, comprehensive Equillium, Inc. stock analysis, charts, news, and expert forecast. Real-time eq stock data and investment insights.
Loading chart...
Company Overview
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Company Information
- CEO
- Bruce D. Steel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
Contact Information
- Website
- https://equilliumbio.com
- Address
- 2223 Avenida De La Playa
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.92)
Business Model & Strategy
Equillium, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Bruce D. Steel, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Equillium, Inc. competes in the Biotechnology within the broader Healthcare. With 57.2 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Equillium, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Equillium, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Equillium, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Equillium, Inc.
- ⚠Investors should consider how Equillium, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
57.19M
P/E Ratio
-2.33
Beta
1.92
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 57.19M market capitalization
- Trading Volume: 1.58M shares traded today
- Price Range: 52-week range of $0.27 - $2.35
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Equillium, Inc.
Equillium, Inc. (EQ) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 57.19M, the company represents a significant player in its market. The stock is currently trading at $1.61 with a positivedaily change of 19.26%.
The company's 35 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -2.33, beta of 1.92, and 52-week price range from $0.27 to $2.35when evaluating investment opportunities.
Why Invest in Equillium, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Bruce D. Steel
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.